Search Results

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

Ludwig Enterprises, Inc is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma, an incurable brain cancer.

Florida Cancer Specialists & Research Institute, LLC announced the formation of a new healthcare analytics subsidiary.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

Florida Cancer Specialists & Research Institute, LLC is proud to announce an initiative aimed at revolutionizing cancer care – the introduction of designated FCS Disease Site Teams for late-phase research and the subsequent formation of the FCS Disease Site Committee.

Providence Therapeutic Holdings Inc. and the Ontario Institute for Cancer Research, Ontario’s largest publicly funded cancer research institute delivering real-world solutions to people affected by cancer, announced the signing of a collaboration agreement for mRNA drug discovery and development.